GoAI
Get started
Pak Fah Yeow International Limited logo

Pak Fah Yeow International Limited

0239.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$2.48

+HK$0.005 · +0.20%

Aug 24, 3:45 PM HKT

0239.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Pak Fah Yeow International Limited, operating with its subsidiaries, specializes in the production, promotion, and distribution of healthcare goods under the Hoe Hin brand. Its market reach spans the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the United Kingdom, and other international territories. The company's operations are categorized into three distinct divisions: Healthcare, Property Investments, and Treasury Investments. Among its key offerings are medicated oils, such as white flower embrocation, along with various ointments and solutions for strain relief, including the floral-scented Fúzai 239 white flower embrocation. Beyond its primary healthcare focus, the firm also commits capital to diverse real estate assets, encompassing commercial, industrial, residential, and car park properties, and additionally provides advertising agency services. This enterprise, established in 1927, maintains its corporate headquarters in Wan Chai, Hong Kong.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
HK
CEO
Wee Sean Gan
Listed since
Dec 18, 1991
Employees
100

Market position

Day range

Current HK$2.48

52-week range

Current HK$2.48

Open
HK$2.475
Previous close
HK$2.475
Volume
12.5K
0.48× average
Average volume
25.88K
Average daily volume
Market cap
772.87M HKD
Beta
0.4
Market reference 1
50-day average
HK$2.3774
+4.32% above average
200-day average
HK$2.4091
+2.94% above average

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends92%66%40%14%Gross margin, FY2021: 49.14%Gross margin, FY2022: 50.31%Gross margin, FY2023: 64.63%Gross margin, FY2024: 85.77%Gross margin, FY2025: 62.25%Operating margin, FY2021: 32.20%Operating margin, FY2022: 31.40%Operating margin, FY2023: 55.15%Operating margin, FY2024: 41.51%Operating margin, FY2025: 51.21%Net margin, FY2021: 27.31%Net margin, FY2022: 20.35%Net margin, FY2023: 40.51%Net margin, FY2024: 33.19%Net margin, FY2025: 42.71%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 49.14%. Gross margin FY2022 50.31%. Gross margin FY2023 64.63%. Gross margin FY2024 85.77%. Gross margin FY2025 62.25%. Operating margin FY2021 32.20%. Operating margin FY2022 31.40%. Operating margin FY2023 55.15%. Operating margin FY2024 41.51%. Operating margin FY2025 51.21%. Net margin FY2021 27.31%. Net margin FY2022 20.35%. Net margin FY2023 40.51%. Net margin FY2024 33.19%. Net margin FY2025 42.71%.

Income trends

Revenue

213.88M HKD-9.72%

Operating income

109.52M HKD+11.36%

Net income

91.35M HKD+16.17%
Income trends across reported periods282.25M HKD190.5M HKD98.76M HKD7.02M HKDRevenue, FY2021: 139.82M HKDRevenue, FY2022: 147.2M HKDRevenue, FY2023: 259.31M HKDRevenue, FY2024: 236.92M HKDRevenue, FY2025: 213.88M HKDOperating income, FY2021: 45.02M HKDOperating income, FY2022: 46.22M HKDOperating income, FY2023: 143.01M HKDOperating income, FY2024: 98.35M HKDOperating income, FY2025: 109.52M HKDNet income, FY2021: 38.19M HKDNet income, FY2022: 29.96M HKDNet income, FY2023: 105.04M HKDNet income, FY2024: 78.63M HKDNet income, FY2025: 91.35M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 139.82M HKD. Revenue FY2022 147.2M HKD. Revenue FY2023 259.31M HKD. Revenue FY2024 236.92M HKD. Revenue FY2025 213.88M HKD. Operating income FY2021 45.02M HKD. Operating income FY2022 46.22M HKD. Operating income FY2023 143.01M HKD. Operating income FY2024 98.35M HKD. Operating income FY2025 109.52M HKD. Net income FY2021 38.19M HKD. Net income FY2022 29.96M HKD. Net income FY2023 105.04M HKD. Net income FY2024 78.63M HKD. Net income FY2025 91.35M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue213.88M HKD236.92M HKD259.31M HKD147.2M HKD139.82M HKD
Cost of goods sold80.74M HKD33.72M HKD91.72M HKD73.14M HKD71.11M HKD
Gross profit133.14M HKD203.2M HKD167.59M HKD74.06M HKD68.71M HKD
Selling, general, and administrative15.04M HKD57.42M HKD16.96M HKD18.81M HKD16.79M HKD
Operating expenses23.62M HKD105.37M HKD89.59M HKD27.83M HKD23.7M HKD
Interest expense546K HKD584K HKD615K HKD644K HKD567K HKD
Depreciation and amortization5.83M HKD7.38M HKD7.39M HKD7.48M HKD7.18M HKD
Operating income109.52M HKD98.35M HKD143.01M HKD46.22M HKD45.02M HKD
Net income91.35M HKD78.63M HKD105.04M HKD29.96M HKD38.19M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.17

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.220.130.04-0.05Q2 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26
Q2 2022, reported Jun 30, 2022: actual -0.007, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 30, 2023: actual 0.103, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual 0.18, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual 0.157, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 27, 2024: actual 0.152, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 0.1, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 25, 2025: actual 0.128, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 25, 2026: actual 0.17, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates138.97M109.34M79.71M50.07MQ2 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26
Q2 2022, reported Jun 30, 2022: actual 56.2M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 30, 2023: actual 91M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual 126.41M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual 132.74M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 27, 2024: actual 132.84M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 104.59M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 25, 2025: actual 94.96M HKD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 25, 2026: actual 119.15M HKD, estimate —, surprise —, Comparison unavailable.

0239.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 0239.HK

research.disclaimer